Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung



PURPOSE: Platinum chemotherapy can be considered to treat metastatic castration-resistant prostate cancer (mCRPC) with features of neuroendocrine differentiation. However, platinum compounds are generally only applied after the failure of multiple prior-line treatment options. This study investigated whether acquired resistance against ionizing radiation or docetaxel chemotherapy-two commonly applied treatment modalities in prostate cancer-influences the cisplatin (CDDP) tolerance in mCRPC cell line models.

METHODS: Age-matched parental as well as radio- or docetaxel-resistant DU145 and PC-3 cell lines were treated with CDDP and their sensitivity was assessed by measurements of growth rates, viability, apoptosis, metabolic activity and colony formation ability.

RESULTS: The data suggest that docetaxel resistance does not influence CDDP tolerance in all tested docetaxel-resistant cell lines. Radio-resistance was associated with sensitization to CDDP in PC-3, but not in DU145 cells. In general, DU145 cells tolerated higher CDDP concentrations than PC-3 cells regardless of acquired resistances. Furthermore, non-age-matched treatment-naïve PC-3 cells exhibited significantly different CDDP tolerances.

CONCLUSION: Like patients, different mCRPC cell lines exhibit significant variability regarding CDDP tolerance. The presented in vitro data suggest that previous radiation treatment may be associated with a moderate sensitization to CDDP in an isogenic and age-matched setting. Therefore, previous radiotherapy or docetaxel chemotherapy might be no contraindication against initiation of platinum chemotherapy in selected mCRPC patients.


Seiten (von - bis)1313-1324
FachzeitschriftJournal of cancer research and clinical oncology
Frühes Online-Datum12 Jan. 2022
PublikationsstatusVeröffentlicht - 1 Juni 2022

Externe IDs

Scopus 85122829354
WOS 000741943700002
unpaywall 10.1007/s00432-022-03914-5
Mendeley 2843b974-0f32-35b7-b979-e036ad9d9b0a
ORCID /0000-0003-3717-3637/work/141545158
ORCID /0000-0002-5247-908X/work/142241927


Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete


  • Cisplatin, Docetaxel, NEPC, Prostate cancer, Radiotherapy, mCRPC